Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Altimmune Inc Is A Late Clinical-Stage Biopharmaceutical Company Developing Therapies For Patients With Serious Liver Diseases. The Company'S Key Candidate, Pemvidutide, Is A Dual-Action Therapy Targeting Both Glucagon And Glp-1 Receptors In A Balanced 1:1 Ratio In Development For The Treatment Of Metabolic Dysfunction-Associated Steatohepatitis (Mash), Alcohol Use Disorder (Aud), And Alcohol-Associated Liver Disease (Ald). The Company Also Plans To Pursue Additional Indications For Pemvidutide That Leverage The Differentiated Clinical Profile Of Pemvidutide.